ArticleHuman vaccines & immunotherapeutics2023
Respiratory syncytial virus-associated hospitalization in children aged <2 years in Spain from 2018 to 2021.
Article in Human vaccines & immunotherapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 26 citations in OpenAlex.
- A bench-to-data analysis workflow for respiratory syncytial virus whole-genome sequencing with short and long-read approaches.Genome medicine · 2026Article
- Hospital burden of Respiratory Syncytial Virus in children in Spain (2016-2022): A retrospective study.Human vaccines & immunotherapeutics · 2025Article
- Dynamics of RSV hospitalization rates in ≤ 2-year-old children between 2020-2023 in Europe.European journal of pediatrics · 2025Article
- Implementing Symptom-Based Predictive Models for Early Diagnosis of Pediatric Respiratory Viral Infections.Viruses · 2025Article
- Interplay between respiratory viruses and cilia in the airways.European respiratory review : an official journal of the European Respiratory Society · 2025Review
- Parental knowledge on the respiratory syncytial virus before the nirsevimab immunization program: Attitudes toward immunization in an autonomous community of Spain.Human vaccines & immunotherapeutics · 2024Article
- Article
- Evaluating the Effectiveness of Nirsevimab in Reducing Pediatric RSV Hospitalizations in Spain.Vaccines · 2024Article
- Impact of twelve immunization-preventable infectious diseases on population health using disability-adjusted life years (DALYs) in Spain.BMC infectious diseases · 2024Article
- Estimated Impact of Nirsevimab on the Incidence of Respiratory Syncytial Virus Infections Requiring Hospital Admission in Children < 1 Year, Weeks 40, 2023, to 8, 2024, Spain.Influenza and other respiratory viruses · 2024Article
- Observational
- Article
- Five Years' Experience with Respiratory Syncytial Virus Among Hospitalized Patients: A Retrospective Study from Jazan, Saudi Arabia.Infection and drug resistance · 2024Article
- The effectiveness of nirsevimab in reducing the burden of disease due to respiratory syncytial virus (RSV) infection over time in the Madrid region (Spain): a prospective population-based cohort study.Frontiers in public health · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Respiratory syncytial virus (RSV) is the leading cause of severe respiratory infections in children. In many countries, changes in RSV hospitalizations have occurred during COVID-19 restriction, with alterations in annual pre-pandemic trends. The objective of this retrospective study was to describe the epidemiology of RSV during the pandemic in Spain (2018-2021) through population-based estimates of hospitalization in children <2 years old. A total of 56,741 hospital discharges were identified with a 2.2% decrease between the beginning and the end of the COVID-19 pandemic resulting in a hospitalization rate of 1,915.89 (95% CI = 1,900.13-1,931.65) hospitalizations per 100,000 children. During the four-year period, a total of 34 deaths were recorded (males 63%, females 37%). The average annual cost to the National Health-Care System of bronchiolitis requiring hospitalization was €49,6 million with an average hospitalization cost per case of €3,054. RSV is a very frequent virus associated with community-acquired pneumonia (CAP) in children under 2 years old, so future preventive interventions should target this age group including vaccination programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.